Saigosoom Napat, Sa-Nguanraksa Doonyapat, O-Charoenrat Eng, Thumrongtaradol Thanawat, O-Charoenrat Pornchai
Division of Head, Neck and Breast Surgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Faculty of Medical Sciences, University College London, London WC1E 6BT, UK.
Cancer Manag Res. 2020 Apr 8;12:2491-2499. doi: 10.2147/CMAR.S237423. eCollection 2020.
Magee Equations have been developed as accurate tools for predicting response and clinical outcomes in breast cancer patients treated with adjuvant systemic therapy using basic clinicopathological parameters. This study aims to evaluate the alternative application of Magee Equation 2 score in predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in hormone receptor (HR)-positive, HER2-negative breast cancer.
Patients with HR-positive, HER2-negative breast cancer who received NAC from January 2010 to May 2018 at Siriraj Hospital, Mahidol University, Thailand, were recruited. Pre-treatment status of HR and HER2 was used to calculate the Magee Equation 2 scores. The pCR rates among different clinicopathological parameters were analyzed. Survival analysis was performed by Log-rank test. Kaplan-Meier survival curves were analyzed.
A total of 215 patients were eligible. The pCR rates for low, intermediate, and high scores were 4.8%, 3.6%, and 23.8%, respectively. Patients with high scores had significantly higher size reduction and pCR rates compared to those with intermediate or low scores (<0.001). Those with high scores had higher rates of locoregional recurrence and death. The patients with high score had significantly lower overall survival (=0.034).
Among patients with HR-positive and HER2-negative breast cancer treated with NAC, Magee Equation 2 might be used as a tool for predicting the pCR and clinical outcome.
马吉方程已被开发为一种精确工具，可利用基本临床病理参数预测接受辅助性全身治疗的乳腺癌患者的反应和临床结果。本研究旨在评估马吉方程2评分在预测激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性乳腺癌新辅助化疗（NAC）后的病理完全缓解（pCR）方面的替代应用。
招募2010年1月至2018年5月在泰国玛希隆大学诗里拉吉医院接受NAC的HR阳性、HER2阴性乳腺癌患者。利用HR和HER2的治疗前状态计算马吉方程2评分。分析不同临床病理参数中的pCR率。采用对数秩检验进行生存分析。分析了Kaplan-Meier生存曲线。
共有215例患者符合条件。低、中、高评分的pCR率分别为4.8%、3.6%和23.8%。与中、低评分患者相比，高评分患者的肿瘤大小缩小率和pCR率显著更高（<0.001）。高评分患者的局部区域复发率和死亡率更高。高评分患者的总生存率显著更低（=0.034）。
在接受NAC治疗的HR阳性、HER2阴性乳腺癌患者中，马吉方程2可作为预测pCR和临床结果的工具。
